For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Nastech Pharmaceutical Company, Inc.

USPTO Granted Patents = 21

Trademarks = 1

Forward Citations = 311

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Steven C Quay (9 out of 93 patents)

Charanjit R Behl (8 out of 10 patents)

Anthony P Sileno (8 out of 18 patents)

4. Vincent D Romeo (8 out of 8 patents)

5. Jorge C deMeireles (5 out of 5 patents)

6. Mary S Kleppe (4 out of 5 patents)

7. Gordon Brandt (4 out of 4 patents)

8. Jeffrey Wenig (4 out of 5 patents)

9. Conor J MacEvilly (3 out of 3 patents)

10. Raja G Achari (3 out of 5 patents)

11. Shamim Ahmed (2 out of 2 patents)

12. Tianquing Liu (2 out of 2 patents)

13. Harish K Pimplaskar (2 out of 2 patents)

14. Wei J Xia (2 out of 2 patents)

15. Henry R Costantino (1 out of 83 patents)

21 patents: Sort by Forward Citations

1. 7863245 - Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity (2011-01-04),

2. 7329725 - Phage displayed Trp cage ligands (2008-02-12),

3. 7244709 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone (2007-07-17),

4. 7229966 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-06-12),

5. 7229636 - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery (2007-06-12),

6. 7186692 - Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-03-06),

7. 7186691 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-03-06),

8. 7166575 - Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity (2007-01-23),

9. 7157426 - Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity (2007-01-02),

10. 6740660 - Nasal delivery of apomorphine (2004-05-25),

11. 6677346 - Methods comprising intranasal morphine (2004-01-13),

12. 6599883 - Nasal delivery of xylitol (2003-07-29),

13. 6451848 - Compositions and methods comprising morphine gluconate (2002-09-17),

14. 6436950 - Nasal delivery of apomorphine (2002-08-20),

15. 6225343 - Compositions and methods comprising morphine gluconate (2001-05-01),

Nastech Pharmaceutical Company, Inc. is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for various diseases. With a strong commitment to research and development, Nastech aims to improve patients' lives by advancing novel drug candidates. Through cutting-edge technology and strategic partnerships, the company strives to deliver effective and targeted solutions that address unmet medical needs. Visit our website to learn more about our transformative treatments and ongoing clinical trials.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

21 Patents

#21 in Bothell, WA

#314 in Washington

#15,151 in US

#29,031 in the World

Bothell, WA, United States of America

Nastech Pharmaceutical Company, Inc.

Forward Citations = 311

24 inventors:

Steven C Quay (9 out of 93 patents)

Charanjit R Behl (8 out of 10 patents)

Anthony P Sileno (8 out of 18 patents)

4. Vincent D Romeo (8 out of 8 patents)

5. Jorge C deMeireles (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…